Teva and Polpharma Biologics Announce Global Licensing Agreement for Ocrelizumab Biosimilar for Multiple Sclerosis

On July 9, 2026, Teva Pharmaceuticals International GmbH (“Teva”) and Polpharma Biologics International AG (“Polpharma Biologics”) announced a global licensing agreement under which Teva will obtain exclusive rights to commercialize Polpharma Biologics’ proposed biosimilar to Genentech’s OCREVUS (ocrelizumab), including both intravenous and subcutaneous formulations, upon regulatory approval.... By: Goodwin